Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by MARK SEUNGWOOK KIM and ANIL K SOOD.
MARK SEUNGWOOK KIM
Connection Strength
2.782
ANIL K SOOD
  1. Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer. Cancer Med. 2024 Aug; 13(15):e70031.
    View in: PubMed
    Score: 0.977
  2. Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer. Mol Cancer Ther. 2020 11; 19(11):2396-2406.
    View in: PubMed
    Score: 0.747
  3. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. Int J Mol Sci. 2024 Jan 20; 25(2).
    View in: PubMed
    Score: 0.235
  4. Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. iScience. 2023 Feb 17; 26(2):106020.
    View in: PubMed
    Score: 0.220
  5. The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene. 2021 01; 40(2):384-395.
    View in: PubMed
    Score: 0.188
  6. GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther. 2019 05; 18(5):969-979.
    View in: PubMed
    Score: 0.169
  7. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009 Sep 02; 101(17):1193-205.
    View in: PubMed
    Score: 0.086
  8. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res. 2008 Sep 01; 14(17):5437-46.
    View in: PubMed
    Score: 0.081
  9. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther. 2008 Jul; 7(7):1098-103.
    View in: PubMed
    Score: 0.079
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.